Which are the causes of Succinic semialdehyde dehydrogenase deficiency?

Succinic semialdehyde dehydrogenase deficiency (SSADH deficiency) is a rare metabolic disorder caused by pathogenic mutations in the ALDH5A1 gene, which prevents the body from properly breaking down the neurotransmitter GABA. This genetic defect leads to the accumulation of toxic succinic semialdehyde in the brain, resulting in the neurological symptoms characteristic of the condition.

What is the genetic cause of Succinic semialdehyde dehydrogenase deficiency?

The primary cause of Succinic semialdehyde dehydrogenase deficiency is an autosomal recessive genetic mutation. Every individual inherits two copies of the ALDH5A1 gene—one from each parent. In patients with this condition, both copies of the gene contain mutations, meaning the body cannot produce a functional version of the SSADH enzyme. Without this enzyme, the metabolic pathway that converts succinic semialdehyde into succinic acid is blocked. This accumulation acts like a "metabolic traffic jam," causing toxic byproducts to build up in the central nervous system, which interferes with normal brain development and function.

Is Succinic semialdehyde dehydrogenase deficiency hereditary?

Yes, Succinic semialdehyde dehydrogenase deficiency is strictly hereditary. Because it follows an autosomal recessive inheritance pattern, parents of an affected child are typically "obligate carriers," meaning they each carry one mutated copy of the ALDH5A1 gene but do not exhibit symptoms themselves. When both parents are carriers, there is a 25% chance with each pregnancy that the child will inherit both mutated copies and develop the disease. Currently, there are no known environmental triggers, dietary factors, or infections that cause this condition; it is fundamentally a result of the genetic blueprint the individual is born with.

How does the metabolic dysfunction occur in the brain?

The core mechanism of Succinic semialdehyde dehydrogenase deficiency involves the GABAergic system, which regulates neuronal excitability. The clinical manifestations are largely due to the accumulation of two specific substances:

• Succinic semialdehyde: A reactive aldehyde that can cause oxidative stress and cellular damage within the brain.


• Gamma-hydroxybutyric acid (GHB): High levels of this substance accumulate because of the metabolic block, acting as a potent neuroinhibitor that contributes to the characteristic symptoms like hypotonia, ataxia, and cognitive delays.

Are the causes of Succinic semialdehyde dehydrogenase deficiency fully understood?

While the genetic etiology is well-defined, researchers are still actively investigating the downstream effects of the disease. We know the ALDH5A1 mutation is the cause, but the variability in clinical presentation—ranging from mild learning disabilities to severe epilepsy—remains a subject of intense research. Scientists are currently exploring how other genetic modifiers or environmental interactions might influence the severity of Succinic semialdehyde dehydrogenase deficiency. Ongoing studies are focused on gene therapy and substrate reduction therapies to bypass the enzyme deficiency, which would fundamentally alter the disease's progression.

What is the difference between a cause and a risk factor?

In the context of Succinic semialdehyde dehydrogenase deficiency, the cause is the specific ALDH5A1 mutation. There are no external "risk factors" (such as lifestyle or exposure) that increase the likelihood of developing the disease. It is a strictly deterministic genetic condition. Understanding this distinction is vital for families, as it removes the burden of "preventable causes" and shifts the focus toward genetic counseling and management.

Next steps

• Consult with a board-certified clinical geneticist to discuss family planning and carrier testing options.


• Connect with the 13 members of the Succinic semialdehyde dehydrogenase deficiency community at DiseaseMaps.org to share experiences and coping strategies.


• Request a referral to a metabolic specialist or pediatric neurologist experienced in managing rare neuro-metabolic disorders.


• Monitor clinical trial registries (such as ClinicalTrials.gov) for emerging research on enzyme replacement or gene-based therapies.

Medical disclaimer: This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment; always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition.

References

• NIH Genetic and Rare Diseases (GARD) Information Center: SSADH deficiency overview.


• Online Mendelian Inheritance in Man (OMIM): Entry #271980 (ALDH5A1 gene).


• Orphanet: Succinic semialdehyde dehydrogenase deficiency (ORPHA:3300).


• The SSADH Association: Patient advocacy and research updates.